Objective To explore the association between immune-related indicators and response to androgen deprivation therapy in patients with advanced prostate cancer.Methods 170 advanced prostate cancer(PC)patients treated in our department from May 2017 to May 2020 were employed as study subjects,all patients received androgen deprivation therapy and follow-up for 1 year.Patients who progressed to castration-resistant prostate cancer(CRPC)during follow-up were included in the poor response group,and the rest were included in the control group.Examination results such as general data,neutrophil to lymphocyte ratio(NLR),platelet-to-lymphocyte ratio(PLR)and monocyte to lymphocyte ratio(MLR)of two groups were comparatively analyzed,Analyzing the factors associated with the response to androgen deprivation therapy by multivariate Cox regression analysis,constructing ROC curve to assess prediction efficiency of NLR and PLR for predicting CRPC within 1 year.Result At the end of follow-up,14 patients who were lost to follow-up and 2 patients who died of other causes were excluded,44 of the remaining 154 cases were included in the poor response group,and 110 cases were included in the control group；There were statistical difference between two groups in the distribution of the number of Gleason score, T stage and N stage.(P<0.05)；NLR and PLR in the poor response group were higher than those in the control group(P<0.05)；There were statistical difference between two groups in the distribution of the number of prostate specific antigen(PSA)level and its nadir(PSA nadir)(P<0.05)；Gleason score≥8 points(HR=3.998,P=0.034),PLR(HR=1.156,P=0.000)and NLR(HR=13.844,P=0.000)were the risk factors of poor response,T2 and T3 stage(HR=0.062、0.211,P=0.048、0.017)were protective factors；AUC of NLR and PLR for predicting CRPC within 1 year were 0.845 and 0.865,there was no statistically significant difference between the AUC of both(P>0.05).Conclusion Baseline NLR and PLR in patients with advanced prostate cancer correlate with the occurrence of CRPC,and both may be effective measures to predict response to androgen deprivation therapy in the future.